Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Assembly Biosciences appoints SVP, pharmaceutical development and manufacturing » 08:17
11/17/20
11/17
08:17
11/17/20
08:17
ASMB

Assembly Biosciences

$5.61 /

+0.025 (+0.45%)

, GOSS

Gossamer Bio

$9.16 /

+0.04 (+0.44%)

Assembly Biosciences…

Assembly Biosciences (ASMB) announced the appointment of Nicole White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing. Prior to joining Assembly Bio, Dr. White headed Process Chemistry at Gossamer Bio (GOSS).

ShowHide Related Items >><<
GOSS Gossamer Bio
$9.16 /

+0.04 (+0.44%)

ASMB Assembly Biosciences
$5.61 /

+0.025 (+0.45%)

ASMB Assembly Biosciences
$5.61 /

+0.025 (+0.45%)

11/06/20 Jefferies
Assembly Biosciences downgraded to Hold from Buy at Jefferies
10/19/20 Truist
Assembly Biosciences initiated with a Buy at Truist
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
GOSS Gossamer Bio
$9.16 /

+0.04 (+0.44%)

10/19/20 H.C. Wainwright
Gossamer Bio price target lowered to $15 from $31 at H.C. Wainwright
10/16/20 Barclays
Gossamer Bio price target lowered to $18 from $22 at Barclays
10/14/20 Cantor Fitzgerald
Gossamer Bio price target lowered to $20 from $33 at Cantor Fitzgerald
10/13/20 Piper Sandler
Gossamer Bio price target lowered to $23 from $30 at Piper Sandler
GOSS Gossamer Bio
$9.16 /

+0.04 (+0.44%)

ASMB Assembly Biosciences
$5.61 /

+0.025 (+0.45%)

  • 30
    Oct
  • 19
    May
  • 12
    Dec
GOSS Gossamer Bio
$9.16 /

+0.04 (+0.44%)

ASMB Assembly Biosciences
$5.61 /

+0.025 (+0.45%)

Hot Stocks
Assembly Biosciences, Door Pharmaceuticals sign collaboration agreement » 08:13
11/16/20
11/16
08:13
11/16/20
08:13
ASMB

Assembly Biosciences

$5.59 /

+0.05 (+0.90%)

Assembly Biosciences and…

Assembly Biosciences and Door Pharmaceuticals announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of hepatitis B virus core protein modulators. Door Pharmaceuticals' innovative discovery platform targets functions of core protein distinct from viral assembly and that have the potential to interfere with viral nucleic acid including cccDNA transcription, providing a strong complement to Assembly Bio's current portfolio. Under the terms of the agreement, Door Pharmaceuticals will build upon its previous efforts to lead and conduct new discovery research, which will be funded by Assembly Bio. In return for an up-front payment and success-based milestones and royalties, Assembly Bio will be granted an exclusive option to license compounds arising from the collaboration and will be responsible for the continued development and commercialization of optioned compounds. Financial details were not disclosed.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$5.59 /

+0.05 (+0.90%)

ASMB Assembly Biosciences
$5.59 /

+0.05 (+0.90%)

11/06/20 Jefferies
Assembly Biosciences downgraded to Hold from Buy at Jefferies
10/19/20 Truist
Assembly Biosciences initiated with a Buy at Truist
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
ASMB Assembly Biosciences
$5.59 /

+0.05 (+0.90%)

  • 12
    Dec
ASMB Assembly Biosciences
$5.59 /

+0.05 (+0.90%)

Hot Stocks
Assembly Biosciences presents data from HBV core inhibitor programs » 08:18
11/13/20
11/13
08:18
11/13/20
08:18
ASMB

Assembly Biosciences

$5.54 /

+0.18 (+3.36%)

Assembly Biosciences…

Assembly Biosciences announced that data from its HBV core inhibitor programs and related research will be highlighted during four poster sessions - including two late-breakers - at the 2020 American Association for the Study of Liver Diseases The Liver Meeting Digital Experience. The posters include data from the company's HBV core inhibitor research and development programs, as well as a collaborative translational study using Assembly Bio's sensitive HBV nucleic acid assays. The Liver Meeting Digital Experience 2020 Presentations: The posters will be made available on the "Events and Presentations" page in the Investors section of assemblybio.com. Vebicorvir, Assembly Bio's Lead HBV Core Inhibitor: Poster Presentation 820: Analysis of the longer-term safety profile of the hepatitis B virus core inhibitor VBR in an open-label extension study: This poster includes data from a controlled comparison of 24 patients receiving placebo + nucleos(t)ide analogs for 24 weeks versus 95 patients receiving Assembly Bio's lead core inhibitor product VBR + NrtI for up to 1.5 years. Data support the differentiated safety profile and continued development of VBR combination therapy. Key Results: The safety profile of combination treatment with VBR+NrtI was similar to placebo+NrtI over a 24-week controlled-comparison and was stable with longer-term treatment of VBR+NrtI up to 1.5 years. Rashes without systemic involvement observed with VBR+NrtI treatment were predominantly Grade 1 resolving without VBR+NrtI interruption. There was no pattern of increased alamine aminotransferase and/or aspartate aminotransferase, indicative of hepatoxicity. Late-Breaking Poster LP37: Changes in viral antigens are more strongly associated with HBV pgRNA than HBV DNA in studies of vebicorvir and NrtI in treatment-naive patients with chronic HBV infection: This poster details the results of post hoc analyses of data from studies of VBR in treatment naive patients with HBeAg positive chronic HBV infection to better understand the correlations between changes in HBV DNA and pgRNA with those of other HBV antigens. Two approaches were used: correlation analyses with a Pearson's coefficient and a Mixed-Effects Model for Repeated Measures. These results demonstrate the importance of pgRNA as a meaningful biomarker for chronic HBV. Key Results: Changes in other HBV antigens are more strongly associated with the change in pgRNA compared with the change in HBV DNA. Correlations between pgRNA and HBeAg and HBcrAg were greater relative to the correlations with HBsAg, likely due to the substantial contribution of HBV integrants to HBsAg levels. A greater than2 log10 decline in pgRNA in patients receiving VBR + entecavir more significantly predicted the decline in the HBeAg and HBcrAg consistent with the second phase decline with core inhibitor treatment reflecting reduction in cccDNA pools. Assembly Bio's Next-Generation of Core Inhibitors: Late-Breaking Poster LP45: Amino acid substitutions in the inhibitor binding pocket of HBV core protein confer differential changes in susceptibility to three generations of HBV core inhibitors: This poster describes the in vitro resistance profiles of Assembly Bio's first-generation core inhibitor, VBR, and next-generation core inhibitor candidates ABI-H2158 and ABI-H3733. Researchers evaluated the antiviral activity of these candidates against known substitutions to the core inhibitor binding pocket. They also assessed whether these substitutions affect the ability of core inhibitors to block cccDNA formation as well as HBV replication through inhibition of pgRNA encapsidation. Key Results: 2158 and 3733 showed greater potency in terms of preventing cccDNA formation compared with VBR and had more favorable resistance profiles against a panel of substitutions. ETV retains activity against all tested core protein substitutions suggesting that combination therapy with NrtIs will prevent viral breakthrough due to pre-existence or potential emergence of core protein substitutions, consistent with the current clinical data. Use of Assembly Bio's Highly Sensitive HBV Assays to Characterize the Association of HBV with HCC: Poster 738: Persistently detectable serum HBV pgRNA is associated with subsequent HCC development in chronic hepatitis B patients receiving chronic NrtI treatment: In this poster, researchers detail findings from a case control study to assess whether residual HBV viraemia is associated with the development of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. The study evaluated 104 chronic HBV patients, 39% of whom had cirrhosis, on greater than or equal to 3 years ETV with unquantifiable HBV DNA by standard assays. Findings highlight the need for more potent viral suppression to further reduce the risk of HCC. Key Results: More sensitive assays revealed that patients still had ongoing replication as evidenced by detection of HBV DNA and pgRNA. More than 50% of chronic HBV patients on ETV with HBV DNAless thanLLOQ by standard assay had persistent viraemia as determined by a more sensitive HBV DNA assay. Detectable viral nucleic acids were associated with a higher 2-year risk of HCC development.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$5.54 /

+0.18 (+3.36%)

ASMB Assembly Biosciences
$5.54 /

+0.18 (+3.36%)

11/06/20 Jefferies
Assembly Biosciences downgraded to Hold from Buy at Jefferies
10/19/20 Truist
Assembly Biosciences initiated with a Buy at Truist
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
ASMB Assembly Biosciences
$5.54 /

+0.18 (+3.36%)

  • 12
    Dec
ASMB Assembly Biosciences
$5.54 /

+0.18 (+3.36%)

Downgrade
Assembly Biosciences downgraded to Hold from Buy at Jefferies » 04:45
11/06/20
11/06
04:45
11/06/20
04:45
ASMB

Assembly Biosciences

$15.89 /

-0.19 (-1.18%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee downgraded Assembly Biosciences to Hold from Buy with a price target of $10, down from $30.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

10/19/20 Truist
Assembly Biosciences initiated with a Buy at Truist
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

  • 12
    Dec
ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

On The Fly
Fly Intel: After-Hours Movers » 18:58
11/05/20
11/05
18:58
11/05/20
18:58
GPRO

GoPro

$6.63 /

+0.42 (+6.76%)

, RMNI

Rimini Street

$3.22 /

+0.08 (+2.55%)

, TTD

Trade Desk

$644.68 /

+12.98 (+2.05%)

, NET

Cloudflare

$58.09 /

+2 (+3.57%)

, ZG

Zillow Group

$104.13 /

+3.62 (+3.60%)

, INSG

Inseego

$9.43 /

+0.55 (+6.19%)

, IAC

IAC

$130.73 /

-0.13 (-0.10%)

, TMUS

T-Mobile

$117.28 /

+1.19 (+1.03%)

, HLF

Herbalife Nutrition

$48.98 /

+1.46 (+3.07%)

, LASR

nLight

$25.23 /

+2.72 (+12.08%)

, YELP

Yelp

$22.01 /

+1.07 (+5.11%)

, ALRM

Alarm.com

$65.12 /

+0.35 (+0.54%)

, DDD

3D Systems

$6.54 /

+0.635 (+10.75%)

, SQ

Square

$175.63 /

+4.46 (+2.61%)

, CARG

CarGurus

$22.12 /

+0.55 (+2.55%)

, MCHP

Microchip

$118.27 /

+4.91 (+4.33%)

, LGF.A

Lionsgate

$7.04 /

+0.18 (+2.62%)

, LGF.B

Lionsgate

$6.60 /

+0.185 (+2.88%)

, TTWO

Take-Two

$168.93 /

+5.17 (+3.16%)

, DLX

Deluxe

$22.90 /

+0.66 (+2.97%)

, SYNA

Synaptics

$82.61 /

+4.31 (+5.50%)

, UPLD

Upland Software

$49.54 /

+2 (+4.21%)

, ROKU

Roku

$224.68 /

+9.1 (+4.22%)

, HALO

Halozyme

$32.85 /

-0.09 (-0.27%)

, MTG

MGIC Investment

$10.24 /

-0.56 (-5.19%)

, MTEM

Molecular Templates

$10.86 /

+0.51 (+4.93%)

, ASMB

Assembly Biosciences

$15.89 /

-0.19 (-1.18%)

, AAOI

Applied Optoelectronics

$10.05 /

+0.985 (+10.87%)

, NEWR

New Relic

$65.14 /

+1.945 (+3.08%)

, PS

Pluralsight

$18.98 /

+0.68 (+3.72%)

, EA

Electronic Arts

$128.35 /

+3.04 (+2.43%)

, PTON

Peloton

$126.61 /

+8.1 (+6.83%)

, STMP

Stamps.com

$253.93 /

+20.4 (+8.74%)

, PLNT

Planet Fitness

$66.67 /

+0.29 (+0.44%)

, ANGI

Angi Homeservices

$11.45 /

-0.05 (-0.43%)

, PSNL

Personalis

$26.73 /

+0.46 (+1.75%)

, CZR

Caesars

$56.13 /

+4.01 (+7.69%)

, VSAT

ViaSat

$33.63 /

+1.42 (+4.41%)

, DBX

Dropbox

$20.11 /

+1.57 (+8.47%)

, RDFN

Redfin

$47.88 /

+0.535 (+1.13%)

, LMNX

Luminex

$23.81 /

+0.67 (+2.90%)

, PK

Park Hotels & Resorts

$10.91 /

+0.44 (+4.20%)

, LYV

Live Nation

$56.45 /

+1.69 (+3.09%)

, EPAY

Bottomline Technologies

$43.52 /

+1.06 (+2.50%)

, WYNN

Wynn Resorts

$80.24 /

+4.14 (+5.44%)

, UBER

Uber

$41.85 /

+0.85 (+2.07%)

Check out this evening's…

ShowHide Related Items >><<
ZG Zillow Group
$104.13 /

+3.62 (+3.60%)

YELP Yelp
$22.01 /

+1.07 (+5.11%)

WYNN Wynn Resorts
$80.24 /

+4.14 (+5.44%)

VSAT ViaSat
$33.63 /

+1.42 (+4.41%)

UBER Uber
$41.85 /

+0.85 (+2.07%)

TTWO Take-Two
$168.93 /

+5.17 (+3.16%)

TTD Trade Desk
$644.68 /

+12.98 (+2.05%)

TMUS T-Mobile
$117.28 /

+1.19 (+1.03%)

SYNA Synaptics
$82.61 /

+4.31 (+5.50%)

STMP Stamps.com
$253.93 /

+20.4 (+8.74%)

SQ Square
$175.63 /

+4.46 (+2.61%)

ROKU Roku
$224.68 /

+9.1 (+4.22%)

RMNI Rimini Street
$3.22 /

+0.08 (+2.55%)

RDFN Redfin
$47.88 /

+0.535 (+1.13%)

PTON Peloton
$126.61 /

+8.1 (+6.83%)

PSNL Personalis
$26.73 /

+0.46 (+1.75%)

PS Pluralsight
$18.98 /

+0.68 (+3.72%)

PLNT Planet Fitness
$66.67 /

+0.29 (+0.44%)

PK Park Hotels & Resorts
$10.91 /

+0.44 (+4.20%)

NEWR New Relic
$65.14 /

+1.945 (+3.08%)

NET Cloudflare
$58.09 /

+2 (+3.57%)

MTG MGIC Investment
$10.24 /

-0.56 (-5.19%)

MTEM Molecular Templates
$10.86 /

+0.51 (+4.93%)

MCHP Microchip
$118.27 /

+4.91 (+4.33%)

LYV Live Nation
$56.45 /

+1.69 (+3.09%)

LMNX Luminex
$23.81 /

+0.67 (+2.90%)

LGF.A Lionsgate
$7.04 /

+0.18 (+2.62%)

INSG Inseego
$9.43 /

+0.55 (+6.19%)

IAC IAC
$130.73 /

-0.13 (-0.10%)

HLF Herbalife Nutrition
$48.98 /

+1.46 (+3.07%)

HALO Halozyme
$32.85 /

-0.09 (-0.27%)

GPRO GoPro
$6.63 /

+0.42 (+6.76%)

EPAY Bottomline Technologies
$43.52 /

+1.06 (+2.50%)

EA Electronic Arts
$128.35 /

+3.04 (+2.43%)

DLX Deluxe
$22.90 /

+0.66 (+2.97%)

DDD 3D Systems
$6.54 /

+0.635 (+10.75%)

DBX Dropbox
$20.11 /

+1.57 (+8.47%)

CZR Caesars
$56.13 /

+4.01 (+7.69%)

CARG CarGurus
$22.12 /

+0.55 (+2.55%)

ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

ANGI Angi Homeservices
$11.45 /

-0.05 (-0.43%)

ALRM Alarm.com
$65.12 /

+0.35 (+0.54%)

AAOI Applied Optoelectronics
$10.05 /

+0.985 (+10.87%)

GPRO GoPro
$6.63 /

+0.42 (+6.76%)

06/29/20 JPMorgan
GoPro assumed with a Neutral at JPMorgan
06/11/20 Morgan Stanley
Morgan Stanley recommends Overweight Sonos, Underweight GoPro pair trade
04/21/20 Raymond James
Sonos Radio could drive 'meaningfully higher' multiples, says Raymond James
03/16/20 Citi
GoPro downgraded to Sell from Neutral at Citi
RMNI Rimini Street
$3.22 /

+0.08 (+2.55%)

10/02/20 Craig-Hallum
Rimini Street initiated with a Buy at Craig-Hallum
08/06/20 Alliance Global Partners
Rimini Street price target raised to $8.50 from $7.50 at Alliance Global Partners
07/28/20 Benchmark
Benchmark starts Rimini Street at Buy with Oracle settlement in 'rearview'
07/28/20 Benchmark
Rimini Street initiated with a Buy at Benchmark
TTD Trade Desk
$644.68 /

+12.98 (+2.05%)

11/04/20 Stifel
Trade Desk price target raised to $500 from $420 at Stifel
11/04/20 Oppenheimer
Trade Desk price target raised to $610 from $530 at Oppenheimer
10/15/20 KeyBanc
Trade Desk downgraded to Sector Weight after 50% rally at KeyBanc
10/15/20 KeyBanc
Trade Desk downgraded to Sector Weight from Overweight at KeyBanc
NET Cloudflare
$58.09 /

+2 (+3.57%)

11/02/20 RBC Capital
Cloudflare price target raised to $55 from $50 at RBC Capital
10/19/20 Baird
Cloudflare price target raised to $62 from $48 at Baird
10/15/20 DA Davidson
Fastly price target lowered to $105 from $115 at DA Davidson
10/15/20 Piper Sandler
Piper says buy Akamai, Cloudflare on Fastly related selloff
ZG Zillow Group
$104.13 /

+3.62 (+3.60%)

10/28/20 Goldman Sachs
Zillow price target raised to $93 from $84 at Goldman Sachs
10/15/20 Piper Sandler
Zillow better positioned than Redfin into Q3 results, says Piper Sandler
10/14/20 Barclays
Zillow price target raised to $70 from $50 at Barclays
10/01/20 Jefferies
Zillow price target raised to $112 from $83 at Jefferies
INSG Inseego
$9.43 /

+0.55 (+6.19%)

09/04/20 Stifel
Inseego 5G opportunity highlighted in meetings with management, says Stifel
08/06/20
Fly Intel: Top five analyst downgrades
08/06/20 Lake Street
Inseego price target raised to $17 from $13 at Lake Street
08/06/20 Roth Capital
Inseego downgraded to Neutral on valuation at Roth Capital
IAC IAC
$130.73 /

-0.13 (-0.10%)

10/29/20 Credit Suisse
IAC price target raised to $199 from $160 at Credit Suisse
09/24/20 Piper Sandler
IAC initiated with an Overweight at Piper Sandler
09/15/20 Jefferies
IAC's key segments saw sequential acceleration in August, says Jefferies
09/14/20 KeyBanc
IAC initiated with an Overweight at KeyBanc
TMUS T-Mobile
$117.28 /

+1.19 (+1.03%)

11/02/20 Deutsche Bank
Deutsche Telekom named short-term buy idea at Deutsche Bank
10/16/20
Fly Intel: Top five analyst initiations
10/16/20 Evercore ISI
T-Mobile resumed with an Outperform at Evercore ISI
10/14/20 Jefferies
Apple price target raised to $140 from $135 at Jefferies
HLF Herbalife Nutrition
$48.98 /

+1.46 (+3.07%)

09/11/20 Jefferies
Herbalife, Nu Skin valuation gaps can close as models transform, says Jefferies
06/22/20 Citi
Citi boosts Herbalife target to $63, opens '90 Day Catalyst Watch'
05/08/20 Jefferies
Herbalife Nutrition price target raised to $45 from $40 at Jefferies
05/08/20 Citi
Herbalife Nutrition price target raised to $56 from $49 at Citi
LASR nLight
$25.23 /

+2.72 (+12.08%)

05/07/20 Craig-Hallum
nLight upgraded to Buy at Craig-Hallum
05/07/20 Craig-Hallum
nLight upgraded to Buy from Hold at Craig-Hallum
01/23/20 Stifel
nLight transferred with Buy, target raised to $26 at Stifel
12/20/19 Piper Sandler
nLight initiated with an Overweight at Piper Jaffray
YELP Yelp
$22.01 /

+1.07 (+5.11%)

09/14/20 KeyBanc
Yelp initiated with a Sector Weight at KeyBanc
09/14/20 KeyBanc
Yelp initiated with a Sector Weight at KeyBanc
08/14/20 Truist
Yelp price target raised to $25 from $22 at Truist
08/13/20 DA Davidson
Yelp price target raised to $28 from $26 at DA Davidson
ALRM Alarm.com
$65.12 /

+0.35 (+0.54%)

09/30/20 Roth Capital
Alarm.com upgraded to Buy from Neutral at Roth Capital
08/03/20 William Blair
Alarm.com downgraded at William Blair on ADT/Google overhang
08/03/20 William Blair
Alarm.com downgraded to Market Perform from Outperform at William Blair
08/03/20 Raymond James
Raymond James sees little near-term impact beyond hardware on Alarm.com from ADT
DDD 3D Systems
$6.54 /

+0.635 (+10.75%)

11/03/20 Craig-Hallum
3D Systems non-core assets sale 'the first of many' catalysts, says Craig-Hallum
10/09/20
Fly Intel: Top five analyst initiations
10/09/20 Berenberg
3D Systems initiated with a Buy at Berenberg
07/16/20 B. Riley Securities
B. Riley FBR resumed 3D Systems, ExOne with Neutral ratings
SQ Square
$175.63 /

+4.46 (+2.61%)

10/30/20 BTIG
BTIG thinks those looking to potentially short Square, H&R Block should wait
10/27/20 Deutsche Bank
Square price target raised to $215 from $180 at Deutsche Bank
10/22/20 Mizuho
Square selloff on 'double whammy' a buying opportunity, says Mizuho
10/21/20 Barclays
Square price target raised to $215 from $185 at Barclays
CARG CarGurus
$22.12 /

+0.55 (+2.55%)

10/23/20
Fly Intel: Top five analyst upgrades
10/23/20 BTIG
CarGurus upgraded to Buy from Neutral at BTIG
08/07/20
Fly Intel: Top five analyst downgrades
08/07/20 BTIG
CarGurus downgraded to Neutral from Buy at BTIG
MCHP Microchip
$118.27 /

+4.91 (+4.33%)

11/04/20 KeyBanc
KeyBanc lays out possible M&A candidates as semi consolidation heats ups
10/19/20 Morgan Stanley
Microchip upgraded to Overweight at Morgan Stanley following underperformance
10/19/20 Morgan Stanley
Microchip upgraded to Overweight from Equal Weight at Morgan Stanley
10/16/20 Mizuho
Microchip price target raised to $128 from $112 at Mizuho
LGF.A Lionsgate
$7.04 /

+0.18 (+2.62%)

11/02/20 Morgan Stanley
Lionsgate assumed with an Equal Weight at Morgan Stanley
09/02/20 Barrington
Lionsgate price target raised to $14 from $10 at Barrington
08/18/20 Barrington
Lionsgate upside 'may be achievable' says Barrington
07/13/20 Goldman Sachs
Lionsgate initiated with a Neutral at Goldman Sachs
LGF.B Lionsgate
$6.60 /

+0.185 (+2.88%)

05/05/20 Canaccord
Lionsgate price target lowered to $13 from $16 at Canaccord
02/10/20 Truist
Lionsgate price target lowered to $15 from $18 at SunTrust
TTWO Take-Two
$168.93 /

+5.17 (+3.16%)

10/21/20 Stifel
Take-Two price target raised to $193 ahead of earnings at Stifel
10/13/20 Deutsche Bank
Take-Two price target raised to $200 from $175 at Deutsche Bank
10/06/20 Piper Sandler
Piper Sandler teen survey shows increased video games engagement
09/23/20 Baird
Demand for PS5, Xbox Series X continues to look 'strong,' says Baird
DLX Deluxe
$22.90 /

+0.66 (+2.97%)

02/12/20 Buckingham
Deluxe price target lowered to $44 from $48 at Buckingham
SYNA Synaptics
$82.61 /

+4.31 (+5.50%)

10/14/20 KeyBanc
Apple iPhone launch positive for Broadcom, Qualcomm, says KeyBanc
09/16/20 KeyBanc
Apple iPhone sales moderated in August, says KeyBanc
08/10/20 KeyBanc
Survey indicates strengthening recovery in Apple iPhone sales, says KeyBanc
UPLD Upland Software
$49.54 /

+2 (+4.21%)

09/02/20 Truist
Upland Software price target raised to $60 from $55 at Truist
08/23/20 Jefferies
Jefferies calls Upland Software a favorite small cap name
08/07/20 Canaccord
Upland Software price target raised to $50 from $42 at Canaccord
08/07/20 Jefferies
Upland Software price target raised to $52 from $40 at Jefferies
ROKU Roku
$224.68 /

+9.1 (+4.22%)

11/05/20 Truist
Roku price target raised to $185 from $110 at Truist
11/04/20 Morgan Stanley
Roku price target raised to $150 from $110 at Morgan Stanley
11/02/20 Wedbush
Roku price target raised to $220 from $160 at Wedbush
10/15/20
Fly Intel: Top five analyst downgrades
HALO Halozyme
$32.85 /

-0.09 (-0.27%)

11/02/20 Piper Sandler
Halozyme price target raised to $37 from $31 at Piper Sandler
09/14/20 JPMorgan
Halozyme resumed with an Overweight at JPMorgan
08/11/20 BMO Capital
Halozyme price target raised to $43 from $35 at BMO Capital
08/11/20 Wells Fargo
Halozyme price target raised to $39 from $31 at Wells Fargo
MTG MGIC Investment
$10.24 /

-0.56 (-5.19%)

11/05/20 Deutsche Bank
MGIC Investment price target raised to $16 from $15 at Deutsche Bank
10/12/20 Susquehanna
Earning should propel mortgage insurers higher, says Susquehanna
10/08/20 MKM Partners
MGIC Investment price target raised to $14 from $12 at MKM Partners
10/06/20 Keefe Bruyette
MGIC Investment upgraded to Outperform from Market Perform at Keefe Bruyette
MTEM Molecular Templates
$10.86 /

+0.51 (+4.93%)

09/08/20 Jefferies
Molecular Templates initiated with a Buy at Jefferies
08/07/20
Molecular Templates files $300M mixed securities shelf
05/12/20 Oppenheimer
Molecular Templates price target raised to $22 from $16 at Oppenheimer
03/25/20
Fly Intel: Top five analyst initiations
ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

10/19/20 Truist
Assembly Biosciences initiated with a Buy at Truist
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
AAOI Applied Optoelectronics
$10.05 /

+0.985 (+10.87%)

11/04/20 B. Riley Securities
Applied Optoelectronics price target lowered to $11 from $14 at B. Riley Securities
10/26/20 Northland
Northland upgrades Applied Optoelectronics to Market Perform on cable outlook
10/26/20 Northland
Applied Optoelectronics upgraded to Market Perform from Underperform at Northland
08/10/20 JPMorgan
JPMorgan keeps Applied Optoelectronics at Underweight, ups price target to $14
NEWR New Relic
$65.14 /

+1.945 (+3.08%)

10/07/20 Berenberg
New Relic initiated with a Buy at Berenberg
09/16/20 Loop Capital
New Relic initiated with a Hold at Loop Capital
09/15/20 Loop Capital
New Relic initiated with a Hold at Loop Capital
08/14/20
Fly Intel: Top five analyst downgrades
PS Pluralsight
$18.98 /

+0.68 (+3.72%)

10/05/20 BTIG
Pluralsight initiated with a Neutral at BTIG
09/02/20
Fly Intel: Top five analyst initiations
09/02/20 DA Davidson
Pluralsight initiated with a Buy at DA Davidson
09/01/20 DA Davidson
Pluralsight initiated with a Buy at DA Davidson
EA Electronic Arts
$128.35 /

+3.04 (+2.43%)

10/26/20 JPMorgan
Electronic Arts price target raised to $155 from $150 at JPMorgan
10/19/20 Cowen
COVID-19 continues to provide tailwind to mobile game spending, says Cowen
10/13/20 Deutsche Bank
Electronic Arts price target raised to $144 from $125 at Deutsche Bank
PTON Peloton
$126.61 /

+8.1 (+6.83%)

11/02/20 Needham
Peloton price target raised to $125 from $110 at Needham
10/27/20 KeyBanc
Peloton promotion with Chase a positive subscriber catalyst, says KeyBanc
10/21/20 Goldman Sachs
Goldman downgrades Peloton to Neutral on valuation, guidance risk
10/21/20 Goldman Sachs
Peloton downgraded to Neutral from Buy at Goldman Sachs
STMP Stamps.com
$253.93 /

+20.4 (+8.74%)

08/07/20 Northland
Stamps.com downgraded to Market Perform from Outperform at Northland
08/07/20 Craig-Hallum
Stamps.com price target raised to $340 from $300 at Craig-Hallum
08/03/20 Craig-Hallum
Stamps.com price target raised to $300 from $230 at Craig-Hallum
05/28/20 Northland
Northland keeps Outperform on Stamps.com, sees e-commerce volume to persist
PLNT Planet Fitness
$66.67 /

+0.29 (+0.44%)

10/12/20 Baird
Planet Fitness designated a Fresh Pick at Baird
09/02/20 Piper Sandler
Planet Fitness price target raised to $81 from $61 at Piper Sandler
08/17/20 Jefferies
Planet Fitness gyms likely to see traffic sabilization, says Jefferies
08/10/20 DA Davidson
Planet Fitness price target lowered to $66 from $86 at DA Davidson
ANGI Angi Homeservices
$11.45 /

-0.05 (-0.43%)

10/29/20
Fly Intel: Top five analyst initiations
10/29/20 Credit Suisse
Angi Homeservices initiated with an Outperform at Credit Suisse
09/24/20 Piper Sandler
Angi Homeservices initiated with a Neutral at Piper Sandler
PSNL Personalis
$26.73 /

+0.46 (+1.75%)

10/19/20 Citi
Personalis initiated with a Buy at Citi
10/07/20 BTIG
Personalis initiated with a Buy at BTIG
08/27/20 H.C. Wainwright
Personalis initiated with a Buy at H.C. Wainwright
08/18/20 Needham
Personalis initiated with a Buy at Needham
CZR Caesars
$56.13 /

+4.01 (+7.69%)

11/02/20 Jefferies
Jefferies upgrades Gaming and Leisure on deal opportunities, tenant health
10/28/20 Ladenburg
Ladenburg reiterates Buy rating on VICI Properties, ups target to $26.50
10/16/20 Morgan Stanley
Caesars price target raised to $68 from $54 at Morgan Stanley
10/08/20 Truist
DraftKings price target raised to $60 from $39 at Truist
VSAT ViaSat
$33.63 /

+1.42 (+4.41%)

05/27/20 JPMorgan
ViaSat price target lowered to $60 from $70 at JPMorgan
05/20/20 William Blair
ViaSat defense contract renewal positive for shares, says William Blair
04/20/20 Barclays
Barclays upgrades ViaSat to Equal Weight on more balanced risk/reward
04/20/20 Barclays
ViaSat upgraded to Equal Weight from Underweight at Barclays
DBX Dropbox
$20.11 /

+1.57 (+8.47%)

09/29/20 Citi
Citi adds Dropbox, removes WPX from 'Value Creators' list
07/31/20
Fly Intel: Top five analyst downgrades
07/31/20 BofA
Dropbox downgraded to Neutral from Buy at BofA
07/20/20
Fly Intel: Top five analyst upgrades
RDFN Redfin
$47.88 /

+0.535 (+1.13%)

10/15/20 Truist
Redfin price target raised to $62 from $58 at Truist
10/15/20 Wedbush
Redfin price target raised to $62 from $48 at Wedbush
09/24/20 Piper Sandler
Redfin initiated with an Overweight at Piper Sandler
LMNX Luminex
$23.81 /

+0.67 (+2.90%)

08/28/20 Piper Sandler
COVID-19 test provider selloff on Abbott approval overdone, says Piper
08/27/20 Piper Sandler
Piper says medical diagnostics stocks oversold on Abbott COVID-19 test news
08/18/20 Piper Sandler
Luminex assumed with an Overweight at Piper Sandler
11/11/19 BTIG
Luminex price target lowered to $32 from $37 at BTIG
PK Park Hotels & Resorts
$10.91 /

+0.44 (+4.20%)

10/13/20 BMO Capital
Park Hotels & Resorts upgraded to Outperform from Market Perform at BMO Capital
10/05/20 Compass Point
Park Hotels & Resorts initiated with a Neutral at Compass Point
09/29/20 BofA
BofA increasing exposure to Lodging, upgrades Park Hotels, Pebblebrook, Sunstone
09/29/20 BofA
Park Hotels & Resorts upgraded to Buy from Underperform at BofA
LYV Live Nation
$56.45 /

+1.69 (+3.09%)

10/27/20 Jefferies
Live Nation downgraded to Hold from Buy at Jefferies
09/21/20 Morgan Stanley
Live Nation price target raised to $56 from $43 at Morgan Stanley
09/03/20 Citi
Live Nation price target raised to $58 from $47 at Citi
07/06/20 Citi
Live Nation price target raised to $47 from $35 at Citi
EPAY Bottomline Technologies
$43.52 /

+1.06 (+2.50%)

08/07/20 RBC Capital
Bottomline Technologies price target raised to $57 from $51 at RBC Capital
05/19/20 Citi
Bottomline Technologies price target raised to $49 from $46 at Citi
05/08/20 Raymond James
Bottomline Technologies price target lowered to $51 from $66 at Raymond James
05/07/20 Craig-Hallum
Bottomline Technologies price target lowered to $53 from $68 at Craig-Hallum
WYNN Wynn Resorts
$80.24 /

+4.14 (+5.44%)

11/02/20 Deutsche Bank
Massachusetts order could impact Wynn, Penn and MGM, says Deutsche Bank
11/02/20
Fly Intel: Top five analyst upgrades
11/02/20 Morgan Stanley
Wynn Resorts upgraded to Overweight at Morgan Stanley after 48% year-to-date dip
11/02/20 Morgan Stanley
Wynn Resorts upgraded to Overweight from Equal Weight at Morgan Stanley
UBER Uber
$41.85 /

+0.85 (+2.07%)

11/05/20 Deutsche Bank
Uber price target raised to $54 from $38 at Deutsche Bank
11/04/20 Wedbush
Uber, Lyft get massive win with Prop 22 passing, overhang removed, says Wedbush
11/04/20 BofA
California vote helps ease 'a big uncertainty' for Uber, says BofA
11/03/20 Truist
Green Dot appears to have won flex debit work at Amazon, says Truist
ZG Zillow Group
$104.13 /

+3.62 (+3.60%)

YELP Yelp
$22.01 /

+1.07 (+5.11%)

WYNN Wynn Resorts
$80.24 /

+4.14 (+5.44%)

VSAT ViaSat
$33.63 /

+1.42 (+4.41%)

UPLD Upland Software
$49.54 /

+2 (+4.21%)

UBER Uber
$41.85 /

+0.85 (+2.07%)

TTWO Take-Two
$168.93 /

+5.17 (+3.16%)

TTD Trade Desk
$644.68 /

+12.98 (+2.05%)

TMUS T-Mobile
$117.28 /

+1.19 (+1.03%)

SYNA Synaptics
$82.61 /

+4.31 (+5.50%)

STMP Stamps.com
$253.93 /

+20.4 (+8.74%)

SQ Square
$175.63 /

+4.46 (+2.61%)

ROKU Roku
$224.68 /

+9.1 (+4.22%)

RMNI Rimini Street
$3.22 /

+0.08 (+2.55%)

RDFN Redfin
$47.88 /

+0.535 (+1.13%)

PTON Peloton
$126.61 /

+8.1 (+6.83%)

PSNL Personalis
$26.73 /

+0.46 (+1.75%)

PS Pluralsight
$18.98 /

+0.68 (+3.72%)

PLNT Planet Fitness
$66.67 /

+0.29 (+0.44%)

PK Park Hotels & Resorts
$10.91 /

+0.44 (+4.20%)

NEWR New Relic
$65.14 /

+1.945 (+3.08%)

NET Cloudflare
$58.09 /

+2 (+3.57%)

MTG MGIC Investment
$10.24 /

-0.56 (-5.19%)

MTEM Molecular Templates
$10.86 /

+0.51 (+4.93%)

MCHP Microchip
$118.27 /

+4.91 (+4.33%)

LYV Live Nation
$56.45 /

+1.69 (+3.09%)

LMNX Luminex
$23.81 /

+0.67 (+2.90%)

LGF.A Lionsgate
$7.04 /

+0.18 (+2.62%)

LASR nLight
$25.23 /

+2.72 (+12.08%)

INSG Inseego
$9.43 /

+0.55 (+6.19%)

IAC IAC
$130.73 /

-0.13 (-0.10%)

HLF Herbalife Nutrition
$48.98 /

+1.46 (+3.07%)

HALO Halozyme
$32.85 /

-0.09 (-0.27%)

GPRO GoPro
$6.63 /

+0.42 (+6.76%)

EPAY Bottomline Technologies
$43.52 /

+1.06 (+2.50%)

EA Electronic Arts
$128.35 /

+3.04 (+2.43%)

DLX Deluxe
$22.90 /

+0.66 (+2.97%)

DDD 3D Systems
$6.54 /

+0.635 (+10.75%)

DBX Dropbox
$20.11 /

+1.57 (+8.47%)

CZR Caesars
$56.13 /

+4.01 (+7.69%)

CARG CarGurus
$22.12 /

+0.55 (+2.55%)

ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

ANGI Angi Homeservices
$11.45 /

-0.05 (-0.43%)

ALRM Alarm.com
$65.12 /

+0.35 (+0.54%)

AAOI Applied Optoelectronics
$10.05 /

+0.985 (+10.87%)

  • 29
    Sep
  • 14
    Aug
  • 12
    Aug
  • 12
    Aug
  • 24
    Jun
  • 10
    Jun
  • 20
    May
  • 17
    Mar
  • 11
    Feb
  • 12
    Dec
  • 21
    Nov
  • 07
    Nov
  • 06
    Nov
YELP Yelp
$22.01 /

+1.07 (+5.11%)

WYNN Wynn Resorts
$80.24 /

+4.14 (+5.44%)

UBER Uber
$41.85 /

+0.85 (+2.07%)

TTWO Take-Two
$168.93 /

+5.17 (+3.16%)

TMUS T-Mobile
$117.28 /

+1.19 (+1.03%)

STMP Stamps.com
$253.93 /

+20.4 (+8.74%)

SQ Square
$175.63 /

+4.46 (+2.61%)

ROKU Roku
$224.68 /

+9.1 (+4.22%)

RDFN Redfin
$47.88 /

+0.535 (+1.13%)

PTON Peloton
$126.61 /

+8.1 (+6.83%)

PLNT Planet Fitness
$66.67 /

+0.29 (+0.44%)

PK Park Hotels & Resorts
$10.91 /

+0.44 (+4.20%)

NEWR New Relic
$65.14 /

+1.945 (+3.08%)

NET Cloudflare
$58.09 /

+2 (+3.57%)

MCHP Microchip
$118.27 /

+4.91 (+4.33%)

LYV Live Nation
$56.45 /

+1.69 (+3.09%)

LMNX Luminex
$23.81 /

+0.67 (+2.90%)

LGF.A Lionsgate
$7.04 /

+0.18 (+2.62%)

INSG Inseego
$9.43 /

+0.55 (+6.19%)

IAC IAC
$130.73 /

-0.13 (-0.10%)

HLF Herbalife Nutrition
$48.98 /

+1.46 (+3.07%)

EA Electronic Arts
$128.35 /

+3.04 (+2.43%)

DBX Dropbox
$20.11 /

+1.57 (+8.47%)

CZR Caesars
$56.13 /

+4.01 (+7.69%)

CARG CarGurus
$22.12 /

+0.55 (+2.55%)

ZG Zillow Group
$104.13 /

+3.62 (+3.60%)

YELP Yelp
$22.01 /

+1.07 (+5.11%)

WYNN Wynn Resorts
$80.24 /

+4.14 (+5.44%)

VSAT ViaSat
$33.63 /

+1.42 (+4.41%)

UBER Uber
$41.85 /

+0.85 (+2.07%)

TTWO Take-Two
$168.93 /

+5.17 (+3.16%)

TTD Trade Desk
$644.68 /

+12.98 (+2.05%)

TMUS T-Mobile
$117.28 /

+1.19 (+1.03%)

SYNA Synaptics
$82.61 /

+4.31 (+5.50%)

STMP Stamps.com
$253.93 /

+20.4 (+8.74%)

SQ Square
$175.63 /

+4.46 (+2.61%)

ROKU Roku
$224.68 /

+9.1 (+4.22%)

RDFN Redfin
$47.88 /

+0.535 (+1.13%)

PTON Peloton
$126.61 /

+8.1 (+6.83%)

PSNL Personalis
$26.73 /

+0.46 (+1.75%)

PS Pluralsight
$18.98 /

+0.68 (+3.72%)

PLNT Planet Fitness
$66.67 /

+0.29 (+0.44%)

NEWR New Relic
$65.14 /

+1.945 (+3.08%)

NET Cloudflare
$58.09 /

+2 (+3.57%)

MCHP Microchip
$118.27 /

+4.91 (+4.33%)

LMNX Luminex
$23.81 /

+0.67 (+2.90%)

LGF.A Lionsgate
$7.04 /

+0.18 (+2.62%)

INSG Inseego
$9.43 /

+0.55 (+6.19%)

IAC IAC
$130.73 /

-0.13 (-0.10%)

HLF Herbalife Nutrition
$48.98 /

+1.46 (+3.07%)

HALO Halozyme
$32.85 /

-0.09 (-0.27%)

GPRO GoPro
$6.63 /

+0.42 (+6.76%)

DDD 3D Systems
$6.54 /

+0.635 (+10.75%)

DBX Dropbox
$20.11 /

+1.57 (+8.47%)

CZR Caesars
$56.13 /

+4.01 (+7.69%)

CARG CarGurus
$22.12 /

+0.55 (+2.55%)

ANGI Angi Homeservices
$11.45 /

-0.05 (-0.43%)

ALRM Alarm.com
$65.12 /

+0.35 (+0.54%)

YELP Yelp
$22.01 /

+1.07 (+5.11%)

WYNN Wynn Resorts
$80.24 /

+4.14 (+5.44%)

VSAT ViaSat
$33.63 /

+1.42 (+4.41%)

UBER Uber
$41.85 /

+0.85 (+2.07%)

TTWO Take-Two
$168.93 /

+5.17 (+3.16%)

TTD Trade Desk
$644.68 /

+12.98 (+2.05%)

TMUS T-Mobile
$117.28 /

+1.19 (+1.03%)

SQ Square
$175.63 /

+4.46 (+2.61%)

ROKU Roku
$224.68 /

+9.1 (+4.22%)

RDFN Redfin
$47.88 /

+0.535 (+1.13%)

PTON Peloton
$126.61 /

+8.1 (+6.83%)

PS Pluralsight
$18.98 /

+0.68 (+3.72%)

PLNT Planet Fitness
$66.67 /

+0.29 (+0.44%)

NET Cloudflare
$58.09 /

+2 (+3.57%)

MTG MGIC Investment
$10.24 /

-0.56 (-5.19%)

MCHP Microchip
$118.27 /

+4.91 (+4.33%)

LYV Live Nation
$56.45 /

+1.69 (+3.09%)

INSG Inseego
$9.43 /

+0.55 (+6.19%)

HLF Herbalife Nutrition
$48.98 /

+1.46 (+3.07%)

GPRO GoPro
$6.63 /

+0.42 (+6.76%)

EA Electronic Arts
$128.35 /

+3.04 (+2.43%)

DDD 3D Systems
$6.54 /

+0.635 (+10.75%)

DBX Dropbox
$20.11 /

+1.57 (+8.47%)

CZR Caesars
$56.13 /

+4.01 (+7.69%)

ANGI Angi Homeservices
$11.45 /

-0.05 (-0.43%)

Hot Stocks
Assembly Biosciences provides update on Study 211 of vebicorvir » 18:32
11/05/20
11/05
18:32
11/05/20
18:32
ASMB

Assembly Biosciences

$15.89 /

-0.19 (-1.18%)

Assembly Biosciences…

Assembly Biosciences provided an update on the ongoing open-label Phase 2 extension study, or Study 211, of vebicorvir in patients with chronic HBV infection. Study 211 is exploring whether sustained virologic response, or SVR, could be achieved after discontinuing therapy in virologically-suppressed patients who had received at least 12-18 months of combination treatment with core inhibitor VBR and a nucleoside analogue reverse transcriptase inhibitor, or NrtI. Study patients who met the treatment stopping criteria discontinued therapy and have been assessed monthly for safety and relapse. The study has not achieved meaningful SVR rates as 39 of 41 patients have now relapsed. Among the patients who have discontinued treatment, 22 of the 23 with HBeAg negative HBV have relapsed, defined as off-treatment quantifiable HBV DNA by the COBAS TaqMan assay. Sixteen of these patients relapsed at post-treatment Week 4, three at post-treatment Week 12, and three patients at post-treatment Week 16. Among the HBeAg positive patients, 17 of 18 relapsed at post-treatment Week 4. Assembly Bio continues to collect and analyze study data and intends to submit more detailed findings to a future medical meeting. Assembly Bio's Phase 2 trials, Study 201 and 202, demonstrated that the addition of VBR to NrtI therapy achieved a more rapid and deeper level of viral suppression than seen with NrtI alone and with a similar safety and tolerability profile. Based on these data, Assembly Bio has reached agreement with the Chinese regulatory body, National Medical Products Administration, Center for Drug Evaluation, and continues discussions with the FDA, on a Phase 3 registrational program for VBR plus NrtI as a chronic suppressive therapy for certain patient populations with chronic HBV infection. The company expects to initiate Phase 3 CST trials in the first half of 2021 in collaboration with BeiGene for the partnered China territory as part of the global registration program. Assembly Bio also continues to advance ABI-H2158 and ABI-H3733, which have demonstrated in preclinical studies 10-fold and 40- to 50-fold higher potency, respectively, than VBR in inhibiting the formation of new cccDNA. A multi-center, randomized, placebo-controlled Phase 2 trial is evaluating 2158 with entecavir versus placebo with entecavir in treatment naive HBeAg positive patients with chronic HBV infection. Additionally, a Phase 1 trial of 3733 is evaluating safety, tolerability, and pharmacokinetics following single ascending dose and multiple ascending dose administrations in healthy subjects. During the first half of 2021, Assembly Bio also intends to initiate a Phase 2 trial to evaluate the triple combination of VBR, Arbutus Biopharma's RNAi therapeutic AB-729 and NrtI in patients with chronic HBV infection. Combining multi-drug regimens with non-overlapping mechanisms has the potential to generate higher response rates in certain HBV patient populations and potentially shorten their duration of treatment. The Company also anticipates initiating a triple combination study in the first half of 2021 to evaluate the addition of interferon to VBR and NrtI.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

10/19/20 Truist
Assembly Biosciences initiated with a Buy at Truist
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

  • 12
    Dec
Earnings
Assembly Biosciences reports Q3 EPS (9c), consensus (75c) » 18:07
11/05/20
11/05
18:07
11/05/20
18:07
ASMB

Assembly Biosciences

$15.89 /

-0.19 (-1.18%)

Cash, cash equivalents…

Cash, cash equivalents and marketable securities were $237.9 million as of September 30, 2020, compared to $226.7 million as of June 30, 2020. This increase is due to the $40.0 million upfront payment received in July 2020 as part of the collaboration agreement with BeiGene offset by cash used in operations. Assembly Bio's cash position is projected to fund operations into the second half of 2022.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

10/19/20 Truist
Assembly Biosciences initiated with a Buy at Truist
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
ASMB Assembly Biosciences
$15.89 /

-0.19 (-1.18%)

  • 12
    Dec
Over a month ago
Conference/Events
Assembly Biosciences management to meet virtually with Mizuho » 04:55
10/29/20
10/29
04:55
10/29/20
04:55
ASMB

Assembly Biosciences

$14.90 /

+0.09 (+0.61%)

Virtual Meetings to be…

Virtual Meetings to be held October 28-29 hosted by Mizuho.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$14.90 /

+0.09 (+0.61%)

ASMB Assembly Biosciences
$14.90 /

+0.09 (+0.61%)

10/19/20 Truist
Assembly Biosciences initiated with a Buy at Truist
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
ASMB Assembly Biosciences
$14.90 /

+0.09 (+0.61%)

  • 12
    Dec
Conference/Events
Assembly Biosciences management to meet virtually with Mizuho » 04:55
10/28/20
10/28
04:55
10/28/20
04:55
ASMB

Assembly Biosciences

$14.81 /

+0.29 (+2.00%)

Virtual Meetings to be…

Virtual Meetings to be held October 28-29 hosted by Mizuho.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$14.81 /

+0.29 (+2.00%)

ASMB Assembly Biosciences
$14.81 /

+0.29 (+2.00%)

10/19/20 Truist
Assembly Biosciences initiated with a Buy at Truist
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
ASMB Assembly Biosciences
$14.81 /

+0.29 (+2.00%)

  • 12
    Dec
Conference/Events
Assembly Biosciences management to meet virtually with Mizuho » 05:55
10/22/20
10/22
05:55
10/22/20
05:55
ASMB

Assembly Biosciences

$15.42 /

+0.01 (+0.06%)

Virtual Meetings to be…

Virtual Meetings to be held October 21-22 hosted by Mizuho.

ShowHide Related Items >><<
ASMB Assembly Biosciences
$15.42 /

+0.01 (+0.06%)

ASMB Assembly Biosciences
$15.42 /

+0.01 (+0.06%)

10/19/20 Truist
Assembly Biosciences initiated with a Buy at Truist
07/21/20 Baird
Assembly Biosciences HBV deal a positive, says Baird
07/20/20 Piper Sandler
BeiGene inked smart deal with Assembly, says Piper Sandler
06/02/20 Mizuho
New clinical paper potentially supports Assembly stoppage criteria, says Mizuho
ASMB Assembly Biosciences
$15.42 /

+0.01 (+0.06%)

  • 12
    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.